BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 1, 2026
Home » Topics » Cardiovascular, Medical technology

Cardiovascular, Medical technology
Cardiovascular, Medical technology RSS Feed RSS

Product image

Endologix begins limited rollout of Alto abdominal stent graft system in Europe

Oct. 16, 2020
By Meg Bryant
Endologix LLC has begun a controlled launch of its Alto abdominal stent graft in Europe, following the receipt of CE mark approval in August. The next-generation Ovation system for polymer endovascular aneurysm repair (EVAR) is designed to provide the broadest indications in infrarenal EVAR grafts, including a 7 mm aortic neck length indication.
Read More
Digital 3d heart model showing FFR values along coronary arteries
TCT Connect 2020

FFR processing fails to blunt costs in U.K. study of patients with stable angina

Oct. 16, 2020
By Mark McCarty
Fractional flow reserve (FFR) processing of computed tomography (CT) images has gained a substantial body of momentum over the past few years, but a recent study posed the question of whether it can save health care systems from excess spending for stable angina.
Read More
Illustration of calcified artery, heart
TCT Connect 2020

Positive results seen with Shockwave IVL in pivotal IDE study

Oct. 16, 2020
By Liz Hollis
Shockwave Medical Inc., which is focused on intravascular lithotripsy (IVL) to treat severely calcified cardiovascular disease, saw its stock value rise Friday (NASDAQ:SWAV), eventually closing at $78.22, up $3.47, or 4.64%, following the presentation of positive results from the Disrupt CAD III trial.
Read More
Product image
TCT Connect 2020

Clinicians not ready to throw dirt on Acurate Neo despite clinical trial failure

Oct. 16, 2020
By Mark McCarty
The history of TAVR devices is evolutionary as much as it is revolutionary, or that is at least the take-away from an Oct. 15 virtual session comparing the Acurate Neo device by Boston Scientific Corp., of Marlborough, Mass., with the Corevalve Evolut R by Dublin-based Medtronic plc.
Read More
Medtronic's headquarters in Minneapolis

Medtronic CEO makes commitment to competitiveness, speed at investor day

Oct. 15, 2020
By Liz Hollis
Medtronic plc management put an emphasis on being nimble and commercializing novel technology at its investor day this week, and analysts appeared to approve of the message. As Wells Fargo’s Larry Biegelsen noted, Dublin-based Medtronic is moving away from a centralized company that is focused on economic value and margin expansion to one that is more decentralized, emphasizing innovation and topline growth.
Read More
Product image

Axon Therapies reports positive results in first-in-human study for neuromodulation approach to heart failure

Oct. 14, 2020
By Tamra Sami
Axon Therapies Inc. has developed an ablation system and method that treats the underlying problems in patients with heart failure with preserved ejection fraction (HFpEF), with an eye toward improving their quality of life.
Read More
Artery and plaque
TCT Connect 2020

Non-culprit lesions blamed for majority of MACE in combo imaging study

Oct. 14, 2020
By Mark McCarty
A study blending intravascular ultrasound and near-infrared spectroscopy, presented at TCT Connect 2020, makes the argument that lipid-rich, nonobstructive lesions are responsible for most major adverse cardiac events after percutaneous treatment.
Read More
3D heart in chest

Spectrawave taps new CEO to lead development of cardiac imaging system

Oct. 14, 2020
By Mary Ellen Schneider
Spectrawave Inc. has named Eman Namati as its CEO with the charge of commercializing its flagship cardiac imaging technology. The 3-year-old, Bedford, Mass.-based medical imaging company has set an ambitious 24-month timeline for getting its photonic imaging technology for coronary artery disease into the clinic.
Read More
Product image

Medtronic launches off two new studies evaluating Evolut TAVR system

Oct. 14, 2020
By Meg Bryant
Medtronic plc has kicked off two clinical trials of its Evolut transcatheter aortic valve replacement (TAVR) system. One study will pit the self-expanding Evolut Pro and Pro+TAVR systems against Edwards Lifesciences Corp.’s balloon-expandable Sapien 3 and Sapien 3 Ultra transcatheter heart valves in small annulus patients.
Read More
Diagram comparing healthy heart organoid to post-heart attack organoid

Human heart organoids provide unmatched insight into cardiac disease and dysfunction

Oct. 12, 2020
By Annette Boyle
Two teams of researchers have developed miniature models of the human heart that beat and function like the full-size organ. The team from Michigan State University (MSU) and Washington University in St. Louis developed a human heart organoid (hHO) that recapitulates embryonic heart development, providing an unmatched view into congenital heart defects. The organoid created by the researchers at the Medical University of South Carolina (MUSC) and Clemson University mimics the tissue dysfunction that occurs following a heart attack.
Read More
Previous 1 2 … 78 79 80 81 82 83 84 85 86 … 107 108 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2026.
  • Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

    ENCALS 2026: From genetics to advancing strategies against ALS

    BioWorld Science
    Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 30, 2026
  • Digital brain with dollar sign

    Investors bet on transformative BCI tech for neuro disorders

    BioWorld
    An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
  • Handshake with DNA, molecules

    Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement

    BioWorld Science
    Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing